Augmentin compared with amoxycillin in treating uncomplicated gonorrhoea.

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Gonorrhoea, a common sexually transmitted infection, is increasingly caused by antibiotic-resistant strains.
• Penicillinase-producing Neisseria gonorrhoeae (PPNG) presents a significant challenge for standard antibiotic therapies.
• Amoxycillin has been a traditional treatment, but its effectiveness is declining due to resistance.

Purpose of the Study:

• To compare the efficacy of Augmentin (amoxycillin/potassium clavulanate) versus amoxycillin in treating uncomplicated gonorrhoea.
• To evaluate treatment outcomes, particularly in patients infected with PPNG strains.
• To assess the effectiveness of Augmentin as a potential treatment for resistant gonorrhoea infections.

Main Methods:

• A randomized, double-blind trial involving 220 patients with uncomplicated gonorrhoea.
• Patients received either Augmentin (amoxycillin 3g + potassium clavulanate 125mg) or amoxycillin 3g.
• All patients received probenecid 1g orally; treatment success was determined by post-treatment cultures.

Main Results:

• Augmentin showed a lower rate of positive cultures post-treatment (6.5%) compared to amoxycillin (13.4%).
• In patients with PPNG infections, treatment failed in all 13 cases receiving amoxycillin.
• Augmentin was effective in treating gonorrhoea caused by PPNG strains, with 10 of 10 PPNG patients responding positively.

Conclusions:

• Augmentin is a more effective treatment for uncomplicated gonorrhoea than amoxycillin alone.
• Augmentin demonstrates significant efficacy against penicillinase-producing Neisseria gonorrhoeae (PPNG) strains.
• The combination of amoxycillin and potassium clavulanate offers a viable therapeutic option for gonorrhoea, including resistant strains.